Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.28
(
1.61%
)
Bitcoin
77,829.76
(
-0.52%
)
News Focus
News Focus
Post# of 405181
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

LilyGDog

Send PM Follow Ignore
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

LilyGDog

Re: LilyGDog post# 349823

Tuesday, 03/02/2021 9:04:57 AM

Tuesday, March 02, 2021 9:04:57 AM

Post# of 405181
Brilacidin’s ability to disrupt viral integrity suggests Brilacidin likely is not subject to resistance developing due to coronavirus variants—unlike current COVID-19 treatments, such as monoclonal antibodies and convalescent plasma, and first-generation COVID-19 vaccines. This mechanism of action supports Brilacidin as a clearly differentiated antiviral in clinical development.

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

Brilacidin in Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating COVID-19.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote